Paul A Friedman Madrigal Pharmaceuticals, Inc. (MDGL) insider trading activity

Paul A Friedman is Director of MADRIGAL PHARMACEUTICALS, INC.. Currently has a direct ownership of 187,164 shares of MDGL, which is worth approximately $82.9 Million. The most recent transaction as insider was on Aug 13, 2025, when has been sold 129,172 shares (Common Stock) at a price of $366.29 per share, resulting in proceeds of $47,314,411. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 187K

0% 3M change

0.38% 12M change

Total Value Held $82.9 Million

PAUL A FRIEDMAN Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Aug 13 2025	SELL Open market or private sale	$47,314,411 $366.29 p/Share	129,172 Reduced 40.83%	187,164 Common Stock
Aug 13 2025	BUY Exercise of conversion of derivative security	$1,220,675 $9.45 p/Share	129,172 Added 28.99%	316,336 Common Stock
Aug 12 2025	SELL Open market or private sale	$15,495,908 $355.37 p/Share	43,605 Reduced 18.9%	187,164 Common Stock
Aug 12 2025	BUY Exercise of conversion of derivative security	$412,067 $9.45 p/Share	43,605 Added 15.89%	230,769 Common Stock
Aug 11 2025	SELL Open market or private sale	$1,123,035 $350.62 p/Share	3,203 Reduced 1.68%	187,164 Common Stock
Aug 11 2025	BUY Exercise of conversion of derivative security	$30,268 $9.45 p/Share	3,203 Added 1.65%	190,367 Common Stock
Jul 18 2025	SELL Open market or private sale	$490,041 $350.03 p/Share	1,400 Reduced 0.74%	187,164 Common Stock
Jul 18 2025	BUY Exercise of conversion of derivative security	$13,229 $9.45 p/Share	1,400 Added 0.74%	188,564 Common Stock
Jul 17 2025	SELL Open market or private sale	$947,267 $350.84 p/Share	2,700 Reduced 1.42%	187,164 Common Stock
Jul 17 2025	BUY Exercise of conversion of derivative security	$25,514 $9.45 p/Share	2,700 Added 1.4%	189,864 Common Stock
Jul 16 2025	SELL Open market or private sale	$9,254,786 $353.56 p/Share	26,176 Reduced 12.27%	187,164 Common Stock
Jul 16 2025	BUY Exercise of conversion of derivative security	$247,363 $9.45 p/Share	26,176 Added 10.93%	213,340 Common Stock
Jun 20 2025	BUY Grant, award, or other acquisition	-	715 Added 0.38%	187,164 Common Stock
Jun 25 2024	BUY Grant, award, or other acquisition	-	714 Added 0.38%	186,449 Common Stock
Apr 08 2024	SELL Open market or private sale	$6,458,479 $245.85 p/Share	26,270 Reduced 12.39%	185,735 Common Stock
Apr 08 2024	BUY Exercise of conversion of derivative security	$248,251 $9.45 p/Share	26,270 Added 11.03%	212,005 Common Stock
Apr 05 2024	SELL Open market or private sale	$6,715,205 $243.19 p/Share	27,613 Reduced 12.94%	185,735 Common Stock
Apr 05 2024	BUY Exercise of conversion of derivative security	$260,942 $9.45 p/Share	27,613 Added 11.46%	213,348 Common Stock
Apr 04 2024	SELL Open market or private sale	$4,577,962 $244.68 p/Share	18,710 Reduced 9.15%	185,735 Common Stock
Apr 04 2024	BUY Exercise of conversion of derivative security	$176,809 $9.45 p/Share	18,710 Added 8.38%	204,445 Common Stock
Apr 03 2024	SELL Open market or private sale	$6,697,448 $244.37 p/Share	27,407 Reduced 12.86%	185,735 Common Stock
Apr 03 2024	BUY Exercise of conversion of derivative security	$258,996 $9.45 p/Share	27,407 Added 11.39%	213,142 Common Stock
Jan 16 2023	SELL Payment of exercise price or tax liability	$549,795 $243.92 p/Share	2,254 Reduced 10.13%	20,001 Common Stock
Jan 16 2023	BUY Grant, award, or other acquisition	-	26,668 Added 50.0%	26,668 Common Stock

Also insider at

PRLD

Prelude Therapeutics Inc Healthcare

ALXN

ALEXION PHARMACEUTICALS, INC.

Director

PAF

Paul A Friedman

Director

West Conshohocken, PA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells MDGL shares.

Notify only if

Value

Insider Trading

Get notified when an Madrigal Pharmaceuticals, Inc. insider buys or sells MDGL shares.

Notify only if

Operation

Value

Type

News

Receive news related to MADRIGAL PHARMACEUTICALS, INC.

Track Activities on MDGL

Account